Celldex Therapeutics (CLDX) Other financing activities (2013 - 2026)

Celldex Therapeutics' Other financing activities history runs 14 years deep, the most recent figure standing at $327000.0 for Q1 2026.

• On a quarterly basis, Other financing activities rose 61.88% year-over-year to $327000.0 in Q1 2026; TTM through Mar 2026 was $2.5 million, a 54.63% decrease from a year earlier, with the FY2025 full-year figure at $2.4 million, down 73.9% from the prior year.
• Other financing activities slipped to $327000.0 in Q1 2026 per CLDX's latest filing, from $1.3 million in the prior quarter.
• Across five years, Other financing activities topped out at $3.8 million in Q1 2024 and bottomed at $63000.0 in Q2 2025.
• The 5-year median for Other financing activities is $694000.0 (2023), against an average of $1.1 million.
• Across the five-year window, Other financing activities surged 2690.98% in 2024 and tumbled 98.3% in 2025, its largest moves.
• Year by year, Other financing activities stood at $1.4 million in 2022, then decreased by 17.42% to $1.2 million in 2023, then plunged by 66.49% to $386000.0 in 2024, then soared by 249.48% to $1.3 million in 2025, then sank by 75.76% to $327000.0 in 2026.
• Per Business Quant, the three latest CLDX Other financing activities figures stand at $327000.0 (Q1 2026), $1.3 million (Q4 2025), and $774000.0 (Q3 2025).